DESIGN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.65 USD | -0.27% |
|
-7.36% | +37.74% |
| Mar. 20 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
| Mar. 20 | Sector Update: Health Care Stocks Down Wednesday Afternoon | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 206M |
|---|---|---|---|---|---|
| Net income 2024 * | -73M | Net income 2025 * | -87M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 231M | Net cash position 2025 * | 168M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.89
x | P/E ratio 2025 * |
-2.5
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.27% | ||
| 1 week | -7.36% | ||
| Current month | -9.43% | ||
| 1 month | -3.95% | ||
| 3 months | +57.33% | ||
| 6 months | +74.64% | ||
| Current year | +37.74% |
1 week
3.55
3.97
1 month
3.424.15
Current year
2.254.15
1 year
1.948.47
3 years
1.9429.16
5 years
1.9450.50
10 years
1.9450.50
| Managers | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
Sean Jeffries
COO | Chief Operating Officer | 44 | 20-12-31 |
Jae B. Kim
CTO | Chief Tech/Sci/R&D Officer | 55 | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
John Schmid
BRD | Director/Board Member | 60 | 20-10-31 |
Simeon George
BRD | Director/Board Member | 46 | 20-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3.65 | -0.27% | 192,880 |
| 24-04-23 | 3.66 | -5.91% | 161,666 |
| 24-04-22 | 3.89 | +5.14% | 248,707 |
| 24-04-19 | 3.7 | -1.07% | 388,557 |
| 24-04-18 | 3.74 | -5.08% | 279,391 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.65
USD
Average target price
4.667
USD
Spread / Average Target
+27.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.74% | 206M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- DSGN Stock
